Clinical-stage biopharmaceutical company DBV Technologies S.A. (DBVT) is approaching a defining stretch in its multi-year pursuit to develop a viable treatment for peanut allergy.
The company's modified Viaskin Peanut patch, designed for children aged four through seven, is currently being evaluated in a Phase 3 efficacy and safety trial known as VITESSE. This study represents a defining moment for DBV, not only in terms of clinical validation but also in its broader strategic trajectory.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com